PureCycle Technologies (PCT) Q3 2024 earnings summary

Executive summary

• Achieved major production milestones at the Ironton Facility, including processing one million pounds of feedstock in a week and 200,000 pounds in a day, with production growing over 200% quarter-over-quarter and significant improvements in reliability and product quality.

• Expanded product portfolio through compounding, enabling multiple product grades and broader customer applications, and began marketing CP2 as a sellable recycled material.

• Strong customer feedback and successful commercial trials across fiber, film, injection molding, and automotive segments, with expectations for meaningful sales in 2025.

• Raised over $105 million in net proceeds through Ironton revenue bonds and capital raises, boosting liquidity and supporting ongoing operations and growth.

• FDA expanded approval in June 2024 allows use of PureCycle's resin in all food contact applications, matching virgin polypropylene.

Financial highlights

• Quarter-end unrestricted and restricted cash balance reached $93.7 million as of September 30, 2024.

• Operating cash expenses for Q3 totaled $23.5 million, down from nearly $35 million in the previous quarter.

• Net loss for Q3 2024 was $90.6 million, with a year-to-date loss of $224.5 million.

• Raised $90 million through preferred and common stock and warrants in September, plus $18–22.5 million from revenue bond sales.

• Additional $118 million in revenue bonds held for future sale to support 2025 liquidity needs.

Outlook and guidance

• Confident in ability to ramp Ironton production to meet growing commercial demand, with focus shifting to matching production rates with sales pipeline.

• Commercial sales for fiber and packaging segments expected to begin in Q4 2024, with additional segments ramping up in 2025.

• Augusta project expected to be a two-line operation with 260 million pounds per year capacity; timeline for construction estimated at 6–10 quarters once financing is secured.

• Material supply to Procter & Gamble for production is planned to begin in Q2 or Q3 of 2025.

• Management believes current unrestricted liquidity is insufficient to fund operations and growth plans, raising substantial doubt about the ability to continue as a going concern, though plans to re-market bonds and operational enhancements are expected to alleviate this.